【摘要】 目的 :探讨血清中可溶性白细胞介素 受体 (SIL - 2 R)与乳癌诊断、病情分析及疗效评价的关系。方法 :应用酶联免疫法 (双抗体夹心法 )对乳癌患者及正常人血清中可溶性白细胞介素 受体 (SIL - 2 R)进行测定。结果 :乳癌患者 SIL - 2 R水平显著高于正常人 (P<0 .0 0 1) ,乳癌患者手术后血清 SIL - 2 R水平较治疗前显著降低 (P<0 .0 1) ,乳癌转移患者治疗前 SIL - 2 R显著高于无转移患者 (P<0 .0 0 1) ,乳癌患者化疗三周再行手术 ,血清 SIL - 2 R水平较单独手术治疗显著降低 (P<0 .0 5 )。三年随访发现 ,乳癌患者中治疗前 SIL - 2 R水平 10 0 0 u/ ml以上的病人 ,术前化疗组三年生存率明显高于单纯手术组 ,二者比较差异显著 (P<0 .0 1)。结论 :此项研究对乳癌诊断、病情分析、疗效诊断及预后评价有一定的指导意义更多还原

【Abstract】 Objective:To study the relations between the serum soluble interleukin-2 receptor(SIL-2R) level and diagnosis of breast cancer,analysis of the disease and evaluation of treatment effects Methods:A two layer antibody sandwich enzymelinked immunosorbent assay(ELISA) was used to measure the serum soluble interlukin-2 receptor(SIL-2R)level in healthy individuals and patients with breast cancer Results:SIL-2R in patients with breast cancer are higher than that in healthy individuals( P< 0 001) The patients with breast cancer after the surgery are abriously lower than before the surgery( P <0 01) SIL-2R in the patients with transferred are much higher than the patients untransferred( P <0 001) In the surgery after 3-weeks chemical treatment,SIL-2R is much lower than the surgery alone( P <0 05) We have discovered after three years follow up that the level of SIL-2R of the patients with breast cancer is over 1000u/ml Three years survival rates of the preopertation chemotherapy group are much higher than those of surgery alone There are significant differences between the two groups (P< 0 01) Conclusion:This study is quite significant in diagnosis of breast cancer,analysis of disease condition,judgement of treatment effects and the prognosis estimation更多还原